glp 1 discontinuation rates Proportion of Patients Who Discontinued GLP-1 RA Therapy, n=4791 Discontinuation rates of GLP-1 medications
Description
You can follow her on Instagram to stay in the loop on her product testing adventures
This led to research in the use of liraglutide, semaglutide and tirzepatide for the purpose of chronic weight management

Tirzepatide (Mounjaro): A dual GIP/GLP-1 agonist approved recently, showing up to 21% weight loss in clinical trials
Patients no longer need to settle for complicated processes or limited access to care
[13] Physicians believe that postprandial epigastric pain is the most common symptom of gastroparesis

[DOI] [PMC free article] [PubMed] [Google Scholar] 33.Kozyrskyj A, Raymond C, Racher A